Amylose resistant starch (HAM‐RS2) supplementation increases the proportion of Faecalibacterium bacteria in end‐stage renal disease patients: Microbial analysis from a randomized placebo‐controlled trial
Hemodialysis International2019Vol. 23(3), pp. 343–347
Citations Over TimeTop 10% of 2019 papers
Michael Laffin, Hamid Tayebi Khosroshahi, Heekuk Park, Luke J. Laffin, Karen Madsen, Hossein Samadi Kafil, Behzad Abedi, Somayeh Shiralizadeh, Nosratola D. Vaziri
Abstract
Supplementation of amylose resistant starch, HAM-RS2, in patients with CKD led to an elevation in Faecalibacterium and decrease in systemic inflammation. Microbial manipulation in CKD patients by using the prebiotic fiber may exert an anti-inflammatory effect through an elevation in the bacterial genera Faecalibacterium.
Related Papers
- → A comparison of placebo effects in clinical analgesic trials versus studies of placebo analgesia(2002)434 cited
- → Altered Placebo and Drug Labeling Changes the Outcome of Episodic Migraine Attacks(2014)391 cited
- → Gender Differences in Placebo Analgesia: Event-Related Potentials and Emotional Modulation(2011)116 cited
- → Conditioned Placebo Analgesia Persists When Subjects Know They Are Receiving a Placebo(2015)116 cited
- → Μελέτη της πολυπαραγοντικής αναλγησίας στο μετεγχειρητικό πόνο μετά από λαπαροσκοπική χολοκυστεκτομή(2014)